Potential Drug-Drug Interaction (DDI) in Type 2 Diabetes Mellitus Outpatients in Palembang: a Retrospective Study

Sonlimar Mangunsong, Fadly Akbar, Mona Rahmi Rulianti, Vera Astuti, Lilis Maryanti, Sarmalina Simamora, Abdul Gani

Abstract


This study aimed to identify and describe potential drug–drug interactions (DDIs) among outpatients with type 2 diabetes mellitus (T2DM) at Hospital X (Palembang, Indonesia) by analysing patient characteristics, patterns of antidiabetic drug use, comorbidities, concomitant medications, and the severity of potential interactions. A descriptive retrospective design was applied using secondary data from outpatient medical records during January–December 2024. From a total of 1,486 records, 316 eligible records were included based on predefined inclusion criteria, with the minimum sample size determined using Slovin’s formula. Potential DDI severity was categorised into major, moderate, and minor. Most patients were female (66.13%) and aged ≥60 years (51.58%). Metformin was the most frequently prescribed antidiabetic drug (25.38%), followed by insulin Apidra (15.45%), insulin Sansulin (14.12%), and glimepiride (12.78%). Potential DDIs were identified in 255 patients (80.69%); across 649 interaction events, most were moderate (93.52%), followed by minor (5.72%) and major (0.75%). The remaining 61 patients (19.31%) had no potential DDIs. Overall, the high utilisation of multi-drug regimens in outpatient T2DM care is associated with substantial exposure to potential DDIs, predominantly of moderate severity, underscoring the need for routine medication review and therapeutic monitoring to improve medication safety, with clinical pharmacists playing an important role in supporting prescribers.

Keywords


Type 2 diabetes mellitus; Potential drug–drug Interactions; Antidiabetic drug utilisation; Polypharmacy; Outpatient care

Full Text:

PDF

References


S. Padhi, A. K. Nayak, and A. Behera, “Type II diabetes mellitus: A review on recent drug-based therapeutics,” Biomedicine & Pharmacotherapy, vol. 131, 110708, 2020. [Online]. Available: https://doi.org/10.1016/j.biopha.2020.110708

World Health Organization, “Diabetes,” 2024. [Online]. Available: https://www.who.int/health-topics/diabetes#tab=tab_1

International Diabetes Federation, IDF Diabetes Atlas, 10th ed., 2021. [Online]. Available: https://diabetesatlas.org/idfawp/resource-files/2021/11/IDFDA10-global-fact-sheet.pdf

Dinas Kesehatan Kota Palembang, Profil Kesehatan Tahun 2018 (Data 2017), 2018. [Online]. Available: https://dinkes.palembang.go.id/ (dokumen lengkap diperlukan untuk URL langsung)

Pharmaceutical Care Network Europe, PCNE Classification V9.1, 2019. [Online]. Available: https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf

L. P. Parulian, E. Listyanti, A. K. Hati, and I. S. Sunnah, “Analysis of polypharmacy and drug interactions among outpatients receiving antihypertensives at Dr. Ario Wirawan Hospital, January–March 2019,” Indonesian Journal of Pharmacy and Natural Product, 2019. [Online]. Available: https://doi.org/10.35473/ijpnp.v2i2.280

A. Hammoud and M. D. Shapiro, “Drug interactions: What are important drug interactions for the most commonly used medications in preventive cardiology?,” Medical Clinics of North America, vol. 106, no. 2, pp. 227–245, 2022. [Online]. Available: https://doi.org/10.1016/j.mcna.2021.11.013

N. Rasdianah, F. Hiola, A. M. A. Suryadi, and A. S. W. Gani, “Drug interactions in type-2 diabetes mellitus patients with comorbidities at Otanaha Hospital, Gorontalo,” Indonesian Journal of Pharmaceutical Education, vol. 1, no. 1, pp. 39–46, 2021. [Online]. Available: https://doi.org/10.22487/ijpe.v1i1.9953

I. B. M. Reyaan, C. Kuning, and I. K. Adnyana, “Potential drug interactions in polypharmacy prescriptions at two community pharmacies in Bandung,” Jurnal Manajemen dan Pelayanan Farmasi (JMPF), vol. 11, no. 3, pp. 145–152, 2021. [Online]. Available: https://doi.org/10.22146/jmpf.56931

O. A. Agustin and F. Fitrianingsih, “Drug–interaction review based on clinical-significance categories among outpatients at Pharmacy X Jambi,” Electronic Journal Scientific of Environmental Health and Disease, vol. 1, no. 1, 2020. [Online]. Available:

O. A. Poluan, W. I. Wiyono, and P. V. Yamlean, “Identification of potential drug interactions among hospitalized type-2 diabetes mellitus patients at Gunung Maria Hospital Tomohon, January–May 2018,” Pharmacon, vol. 9, no. 1, pp. 38–46, 2020. [Online]. Available: https://doi.org/10.35799/pha.9.2020.31071

V. R. Rohmatulloh, B. Pardjianto, and L. S. Kinasih, “Association of age and sex with incidence of type-2 diabetes mellitus based on four diagnostic criteria at Karsa Husada Hospital Batu,” Prepotif: Jurnal Kesehatan Masyarakat, vol. 8, no. 1, 2024. [Online]. Available: https://doi.org/10.31004/prepotif.v8i1.27198

R. Arania, T. Triwahyuni, F. Esfandiari, F. R. Nugraha, and A. Moeloek, “Association of age, sex, and education with diabetes mellitus at Klinik Mardi Waluyo, Central Lampung,” Jurnal Medika Malahayati, vol. 5, no. 3, 2021. [Online]. Available: https://doi.org/10.33024/jmm.v5i3

S. Oktavia, E. Budiarti, F. Masra, D. Rahayu, and B. Setiaji, “Socio-demographic factors associated with type-2 diabetes mellitus,” Jurnal Ilmiah Permas, vol. 12, no. 4, pp. 1039–1042, 2022. [Online]. Available: http://journal.stikeskendal.ac.id/index.php/PSKM

D. P. V. Pinto da Costa Viana, L. Caseri Câmara, and R. Borges Palau, “Menopause as a critical turning point in lipedema: The estrogen receptor imbalance, intracrine estrogen, and adipose tissue dysfunction model,” International Journal of Molecular Sciences, vol. 26, no. 15, 7074, 2025. [Online]. Available: https://doi.org/10.3390/ijms26157074

K. Komariah and R. Sri, “Association of age, sex, and body-mass index with fasting blood glucose among type-2 diabetes mellitus patients at Proklamasi Primary Clinic, Depok,” Jurnal Kesehatan Kusuma Husada, vol. 11, no. 1, pp. 41–50, 2020. [Online]. Available: https://doi.org/10.34035/jk.v11i1.412

A. Firdiawan, R. Fadhilah, Y. L. Imanda, and N. Nurleni, “Drug-use patterns and characteristics of hospitalized type-2 diabetes mellitus patients at Siti Fatimah General Hospital, South Sumatra,” Jurnal Ilmiah Bakti Farmasi, vol. 7, no. 2, 2023. [Online]. Available: https://doi.org/10.61685/jibf.v7i2.92

Perkumpulan Endokrinologi Indonesia (PERKENI), Guidelines for the Management and Prevention of Type-2 Diabetes Mellitus in Indonesian Adults, Jakarta: PB PERKENI, 2021. [Online]. Available: https://pbperkeni.or.id

D. Lu, X. Ou, T. Wang, and G. Xu, “Triglycerides as a mediator in the hyperuricemia–diabetes link: Insights from a hypertensive Chinese population,” Frontiers in Endocrinology, vol. 16, 1645766, 2025. [Online]. Available: https://doi.org/10.3389/fendo.2025.1645766

S. Althubait, H. Perkins, R. Cote, T. Wein, J. Minuk, E. Erhensperger, L. Durcan, A. Moussaddy, and L. Vieira, “Prevalence of undiagnosed risk factors in patients with first-ever ischemic stroke treated at MUHC: A retrospective analysis,” Journal of Personalized Medicine, vol. 15, no. 9, 433, 2025. [Online]. Available: https://doi.org/10.3390/jpm15090433

S. Dharma, Textbook of Cardiology: Coronary Heart Disease, Jakarta: UI Publishing, 2020. Available: https://scholar.ui.ac.id/en/publications/buku-ajar-kardiologi-penyakit-jantung-koroner/

T. Kelesidis and E. Canseco, “Quinolone-induced hypoglycemia: A life-threatening but potentially reversible side effect,” The American Journal of Medicine, vol. 123, no. 2, pp. e5–e6, 2010. [Online]. Available: https://doi.org/10.1016/j.amjmed.2009.07.022

S. H. Hammadi, S. S. AL-Ghamdi, A. I. Yassien, and S. D. AL-Hassani, “Aspirin and blood glucose and insulin resistance,” Open Journal of Endocrine and Metabolic Diseases, vol. 2, no. 2, pp. 16–26, 2012. [Online]. Available: https://doi.org/10.4236/ojemd.2012.22003

L. L. Brunton, R. Hilal-Dandan, and B. C. Knollmann, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th ed. New York, NY, USA: McGraw-Hill Education, 2018. [Online]. Available: https://accessmedicine.mhmedical.com/book.aspx?bookID=2189

Drugs.com, “Drug Interaction Checker,” 2025. [Online]. Available: https://www.drugs.com/interactions-check.php?drug_list=11760,13440,21180&types%5B%5D=moderate&professional=1

X. Hu, W. Xu, S. Lin, C. Zhang, C. Ling, and M. Chen, “Development and validation of a hypoglycemia risk model for intensive insulin therapy in patients with type-2 diabetes,” Journal of Diabetes Research, 7292108, 2020. [Online]. Available: https://doi.org/10.1155/2020/7292108

K. Stockley, Stockley’s Drug Interactions, 9th ed. London, U.K.: Pharmaceutical Press, 2010. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC3066588/

X. Wen, J.-S. Wang, J. T. Backman, K. T. Kivistö, and P. J. Neuvonen, “Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9,” Drug Metabolism and Disposition, vol. 29, no. 11, pp. 1359–1361, 2001. [Online]. Available: https://dmd.aspetjournals.org/content/29/11/1359

D. A. Sari, G. Samodra, and I. Y. Kusuma, “Molecular mechanism of glucocorticoid-induced hyperglycemia,” Pharmacy Reports, vol. 1, no. 1, p. 1, 2021. [Online]. Available: https://doi.org/10.51511/pr.1

J. Li, N. Zhang, B. Ye, W. Ju, B. Orser, J. E. Fox, M. B. Wheeler, Q. Wang, and W. Y. Lu, “Non-steroidal anti-inflammatory drugs increase insulin release from β cells by inhibiting ATP-sensitive potassium channels,” British Journal of Pharmacology, vol. 151, no. 4, pp. 483–493, 2007. [Online]. Available: https://doi.org/10.1038/sj.bjp.0707259

H. Z. Huri and H. F. Wee, “Drug-related problems in type-2 diabetes patients with hypertension: A cross-sectional study,” BMC Endocrine Disorders, vol. 13, no. 1, p. 2, 2013. [Online]. Available: https://doi.org/10.1186/1472-6823-13-2




DOI: https://doi.org/10.37311/ijpe.v6i1.34468

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 Sonlimar Mangunsong, Fadly Akbar, Mona Rahmi Rulianti, Vera Astuti, Sarmalina Simamora, Lilis Maryanti, Abdul Gani

Creative Commons License
Indonesian Journal of Pharmaceutical Education is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.